Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, clopidogrel (Plavix®) cannot be endorsed for use within NHS Wales in combination with aspirin in adult patients with moderate to high-risk Transient Ischaemic Attack (TIA) (ABCD2 score ≥4) or minor Ischemic Stroke (IS) (NIHSS ≤3) within 24 hours of either the TIA or IS event. |
||
|
||
Medicine details |
||
| Medicine name | clopidogrel (Plavix®) | |
| Formulation | 75 mg and 300 mg film-coated tablets | |
| Reference number | 4823 | |
| Indication | In combination with aspirin in adult patients with moderate to high-risk Transient Ischaemic Attack (TIA) (ABCD2 score ≥4) or minor Ischemic Stroke (IS) (NIHSS ≤3) within 24 hours of either the TIA or IS event |
|
| Company | Sanofi-Aventis Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/06/2021 | |